2 models fit Globus Medical Inc. Class A Common Stock and they disagree: 0 of 2 land within 15% of the average.
Two or more of our models back this value.
Discount(i)Bronze44
Valued as a growth company: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
ACCE opinionGlobus Medical Inc. Class A Common Stock (GMED)
Fair value (2 models)
$99.82
ACCE price target
$79.00
Rating
Undervalued
Horizon
12 months
Fair value published on 17 Oct 2026, 00:00 CEST; previously $96.75 since 12 Oct 2026, 00:00 CEST.
ACCE price target published on 10 Oct 2026, 00:00 CEST.
Price used: $81.41 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, EV/EBITDA comparison, and P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
18.4% below
+22.6% to fair value
ACCE score
58
out of 100
Analysts
67% buy
15 covering
P/E
20.9x
forward 15.1x
1-year return
+29.6%
Dividend yield
0.00%
Globus Medical Inc. Class A Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Globus Medical makes spinal implants, navigation and robotics systems (ExcelsiusGPS, ExcelsiusFlex) and biologics used in spine surgery, selling mostly to hospitals and surgeons in the US. Its edge is a large, long-standing catalog of implant designs and a surgeon-training base that makes switching costly, which shows up in a 69.0% gross margin and a 24.8% operating margin. Revenue growth of 5.9% is modest, but the robotics installed base, which pulls through higher-margin implant volume, is the lever to watch. At a trailing P/E of 20.2 and a forward P/E of 13.9, the market is pricing in a meaningful drop in earnings growth or a skeptical view of the margin profile, and the 11.8% ROE is respectable rather than exceptional for a company with this margin structure. The score of 58/100 and absence from major indices suggest the name gets little institutional attention, so it merits a deeper look at whether robotics adoption is accelerating enough to justify the gap between trailing and forward multiples.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
moderate
Earnings declining despite revenue growth
Revenue grew 5.9% year over year but earnings fell 26.2%, so profit is not keeping pace with sales. Net margin is still 17.0%, but the trend bears watching.
moderate
Score down sharply in 90 days
The ACCE score fell 20 points, from 76 to 56, with the momentum sub-score at 45. The deterioration is concentrated in growth and momentum rather than balance sheet or quality.
moderate
Insider selling with no buying
Insiders disclosed $8.32M in sales and $0.00M in purchases across the last 10 disclosures. Insider ownership is only 0.6%, so the signal is modest but one-directional.
AI research notes
AI-assisted·How I use AIWritten Oct 21, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Free cash flow over the last twelve months reached $589M, a solid cash engine for a company with little debt.
The stock trades at 14.6x forward earnings, well below the sector median of 24.2x, so investors pay less per unit of profit.
The latest quarter beat expectations, with earnings per share of 1.34 against 1.12 expected, a 19.6% surprise.
Why it could disappoint
Revenue grew only 5.9% over the past year, far below the 30.1% annual pace averaged across five years.
Return on invested capital of 9.4% and return on equity of 11.8% are modest for a company generating these cash flows.
The share price implies only 3.9% yearly cash flow growth over five years, which leaves the valuation sensitive to a 5.2% risk-free rate.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 5, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where GMED's valuation models land
Price
$81.41
Model fair value
$99.82
Model range
$78.54 to $121
Fair value $99.82
Price $81.41
The price sits inside the model range.
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
P/E comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores